Clinical Trials Browser

Phase 2 × INDUSTRY × irofulven × Clear all

NCT03643107 2025-01-23

Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Phase 2 Completed

Metastatic Castration-Resistant Prostate Cancer Patients

NCT00124527 2021-06-16

Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer

Phase 2 Completed

Thyroid Neoplasms

NCT00124566 2016-01-18

Study of Irofulven in Patients With Hormone-refractory Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms